Media Newsroom of

ReGenTree, LLC

ReGenTree is a U.S. joint venture company owned by GtreeBNT Co., Ltd, and RegeneRx Biopharmaceuticals, Inc. specifically to develop RGN-259 in the U.S.A. and Canada for ophthalmic indications.

ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO

ReGenTree, LLC (the “Company”), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced today that the Company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO…

ReGenTree Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

ReGenTree Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

ReGenTree LLC (the "Company"), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced today the outcome of discussions with FDA regarding the results of the completed phase 3 clinical trial (ARISE-2) and the future development requirements for a New Drug Application…

ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Confirmed in Both Signs and Symptoms

ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Confirmed in Both Signs and Symptoms

ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, announced today that the Phase 3 clinical trial (ARISE-2) of RGN-259 for the treatment of dry eye has been completed. The ARISE-2 trial investigated the safety and efficacy of RGN-259 compared…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login